drugset
drugset / Trial / NCT00718601

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

NCT00718601 ↗

Phase 1 Completed 40 enrolled Geron Corporation
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.

Timeline

Start
2008-07
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Imetelstat Oligonucleotide (other) — Intravenous

Indications

plasma cell myeloma